Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Ho Hong

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 10